New Patent for SN-38 Conjugates at IMMU - Analyst Blog
January 02 2014 - 2:50PM
Zacks
Immunomedics, Inc.
(IMMU) announced the issuance of U.S. patents (patent no. 8,617,558
and 8,617,518) for its antibody-SN-38 conjugates. Immunomedics’
shares gained more than 10% on Dec 31 following the news. We note
that SN-38, the active metabolite of irinotecan (a camptothecin
analogue), is approved for the treatment of metastatic colorectal
cancer.
The first patent (patent no. 8,617,558) is expected to expire in
Dec 2023. The patent is related to Immunomedics’ proprietary linker
technology for conjugating SN-38 to its humanized antibodies for
targeted delivery of the potent drug for the treatment of tumor.
Moreover, Immunomedics is prosecuting additional patents for its
antibody-drug conjugates in other countries as well.
Results from early dose-escalation studies on two antibody-SN-38
conjugates (IMMU-132 and 130) have shown evidence of shrinkage in
difficult-to-treat solid tumor among patients who were unsuccessful
with multiple prior therapies. Immunomedics is developing IMMU-132
and IMMU-130 in phase II studies in patients suffering from solid
tumor.
The other patent (patent no. 8,617,518) is scheduled to expire in
Dec 2027. This patent will cover the methods and compositions of
labeling peptides and other molecules with the diagnostic
radioisotope, fluorine-18 (F-18) or the magnetic resonance imaging
(MRI) label, fluorine-19 (F-19).
The company has progressed well on its oncology portfolio in the
last few quarters. However, we note that the oncology market has
big players like Roche (RHHBY).
Immunomedics currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks include Jazz Pharmaceuticals
(JAZZ) and Forest Laboratories Inc. (FRX). Both
the stocks carry a Zacks Rank #1 (Strong Buy).
FOREST LABS A (FRX): Free Stock Analysis Report
IMMUNOMEDICS (IMMU): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2023 to Aug 2024